Wall Street analysts expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.46). Neurocrine Biosciences reported earnings of ($0.90) per share in the same quarter last year, which suggests a positive year over year growth rate of 64.4%. The company is expected to announce its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Neurocrine Biosciences will report full year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.66) to $0.37. For the next fiscal year, analysts expect that the business will report earnings of $1.78 per share, with EPS estimates ranging from $0.67 to $2.50. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million for the quarter, compared to analyst estimates of $94.00 million. During the same period in the prior year, the company posted ($0.51) EPS.
In other news, insider Darin Lippoldt sold 15,237 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. Following the completion of the transaction, the insider now directly owns 28,394 shares in the company, valued at approximately $2,129,550. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Haig P. Bozigian sold 75,873 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $90.00, for a total transaction of $6,828,570.00. Following the transaction, the insider now owns 18,041 shares of the company’s stock, valued at $1,623,690. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 399,589 shares of company stock valued at $32,443,795. Company insiders own 4.80% of the company’s stock.
A number of large investors have recently modified their holdings of NBIX. Dimensional Fund Advisors LP lifted its stake in Neurocrine Biosciences by 6.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock valued at $8,105,000 after purchasing an additional 10,782 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. Nationwide Fund Advisors lifted its stake in Neurocrine Biosciences by 3.2% in the 3rd quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock valued at $7,620,000 after purchasing an additional 3,800 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in Neurocrine Biosciences in the 3rd quarter valued at about $286,000. Finally, State Board of Administration of Florida Retirement System lifted its stake in Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock valued at $7,380,000 after purchasing an additional 810 shares during the last quarter.
Neurocrine Biosciences (NASDAQ NBIX) traded down $1.84 on Monday, hitting $90.59. 483,663 shares of the company were exchanged, compared to its average volume of 802,828. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20. Neurocrine Biosciences has a 1-year low of $39.21 and a 1-year high of $92.98. The company has a market cap of $8,090.00, a PE ratio of -55.58 and a beta of 0.30.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/03/12/zacks-analysts-expect-neurocrine-biosciences-inc-nbix-to-announce-0-32-earnings-per-share.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.